Literature DB >> 2615523

Pharmacokinetics of 4' epi-adriamycin after morning and afternoon intravenous administration.

S Eksborg1, U Stendahl, K Antila.   

Abstract

The chronopharmacokinetics of 4' epi-adriamycin (Epi) have been studied in ten patients with gynecological malignancies. The drug (45 mg m-2) was administered as a short time (5.0 min) intravenous infusion at 7 a.m. and 7 p.m., in a randomized cross-over design. The pharmacokinetics of Epi were evaluated according to the statistical moment theory. Morning and afternoon dosing of Epi was not bioequivalent. The area under the plasma concentration-time curve (AUC), the maximum plasma concentration (Cmax), mean residence time (MRT) and the terminal half-life time (t1/2) could differ by more than 35% after morning and afternoon dosing. The inter-individual variation of AUC and Cp,max were larger after morning dosing than after afternoon dosing (P less than 0.04). The morning dose of Epi resulted in higher values of AUC in seven of the ten treated patients as compared to the afternoon dose. The terminal half-life times were shorter in eight of the patients after the morning dose.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2615523     DOI: 10.1007/bf02985190

Source DB:  PubMed          Journal:  Med Oncol Tumor Pharmacother        ISSN: 0736-0118


  18 in total

1.  Liquid chromatography in anticancer drug research with special reference to anthraquinone glycosides.

Authors:  S Eksborg; H Ehrsson
Journal:  J Pharm Biomed Anal       Date:  1984       Impact factor: 3.935

2.  Circadian changes in the pharmacokinetics and cardiovascular effects of oral propranolol in healthy subjects.

Authors:  B Langner; B Lemmer
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

3.  The use of non-parametric methods in the statistical analysis of the two-period change-over design.

Authors:  G G Koch
Journal:  Biometrics       Date:  1972-06       Impact factor: 2.571

4.  Use of confidence intervals in analysis of comparative bioavailability trials.

Authors:  W J Westlake
Journal:  J Pharm Sci       Date:  1972-08       Impact factor: 3.534

5.  Generalization of distribution--free confidence intervals for bioavailability ratios.

Authors:  V W Steinijans; E Diletti
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

6.  Pharmacokinetics of temazepam after day-time and night-time oral administration.

Authors:  F O Müller; M Van Dyk; H K Hundt; A L Joubert; H G Luus; G Groenewoud; G C Dunbar
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

7.  Pharmacokinetic case for giving 6-mercaptopurine maintenance doses at night.

Authors:  A M Langevin; G Koren; S J Soldin; M Greenberg
Journal:  Lancet       Date:  1987-08-29       Impact factor: 79.321

Review 8.  Circadian changes of drug disposition in man.

Authors:  A Reinberg; M H Smolensky
Journal:  Clin Pharmacokinet       Date:  1982 Sep-Oct       Impact factor: 6.447

Review 9.  The clinical application of chronobiology to oncology.

Authors:  W J Hrushesky
Journal:  Am J Anat       Date:  1983-12

10.  Clinical toxicity of 4'-epi-doxorubicin (epirubicin).

Authors:  F Ganzina; N Di Pietro; O Magni
Journal:  Tumori       Date:  1985-06-30
View more
  1 in total

1.  Epirubicin as a single agent therapy for the treatment of breast cancer--a pharmacokinetic and clinical study.

Authors:  S Eksborg; L Hardell; N O Bengtsson; M Sjödin; B Elfsson
Journal:  Med Oncol Tumor Pharmacother       Date:  1992
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.